Avio Smart Market Stack Limited has announced a strategic investment of ₹4 crore in Huwel Lifesciences Private Limited, marking another significant step in the company's expansion into the healthcare sector. The investment was disclosed to stock exchanges on April 8, 2026, in compliance with regulatory requirements.

Investment Details

The investment structure demonstrates a calculated approach to acquiring equity in the molecular diagnostics company:

Target Company Profile

Huwel Lifesciences Private Limited operates in the lifescience and health industry, focusing on critical healthcare solutions. The company was incorporated on February 10, 2015, and has established itself as a key player in the molecular diagnostics space.

Business Operations

Huwel specializes in the development, manufacturing, and supply of:

• Molecular diagnostic kits
• Medical devices
• In-vitro diagnostic solutions

The company serves hospitals, laboratories, and research institutions by providing essential products for disease detection and healthcare testing.

Financial Performance

Huwel's revenue performance over the past three years shows significant variation:

Strategic Rationale

The acquisition aims to derive operational and financial synergies between the two companies. This investment represents a continuation of Avio Smart Market Stack's strategic expansion, following their earlier intimation dated February 27, 2026.

The transaction does not fall within the ambit of related party transactions, and the promoter/promoter group has no interest in the target entity. No governmental or regulatory approvals are required for this acquisition.

Implementation Timeline

According to the disclosure, this tranche of investment has been completed, with remaining tranches to be executed in accordance with the terms and conditions specified in the Shareholders' Agreement. The company is based in Patancheru, Telangana, India.

Avio Smart Market Stack Limited (formerly known as Bartronics India Limited) announced significant board changes following its meeting held on April 02, 2026. The company addressed key governance matters including director transitions and committee restructuring in compliance with SEBI regulations.

Director Cessation and Appreciation

The Board formally acknowledged the completion of tenure for Mrs. Sujata Cyril Borde (DIN: 09620880), who ceased to be an Independent Director upon completion of her first term of three years with effect from March 28, 2026. The Board and Management placed on record their sincere appreciation for her valuable contributions, guidance, and services rendered during her association with the company.

Re-appointment of Independent Director

Based on the recommendation of the Nomination and Remuneration Committee, the Board approved the re-appointment of Mr. Krishna Kishore Madicharla (DIN: 07582428) as Independent Director for a second term of five years with effect from March 28, 2026, subject to shareholder approval.

The company confirmed that Mr. Madicharla has not been debarred from holding the office of Director by virtue of any order issued by SEBI or other authorities. His appointment aligns with independence criteria outlined under Section 149(6) of the Companies Act and SEBI regulations. He is not related to any Directors, Key Managerial Personnel, Promoters, or Promoter group of the company.

Committee Reconstitution

In view of the directorship changes, the Board approved reconstitution of key governance committees with effect from April 01, 2026:

• Nomination & Remuneration Committee
• Audit Committee
• Stakeholder Relationship Committee

Meeting Details and Compliance

The Board meeting commenced at 10:30 a.m. and concluded at 11:30 a.m. on April 02, 2026. All decisions were made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company provided comprehensive disclosures as required under SEBI regulations, including detailed profiles and compliance confirmations for the director changes.

Company Secretary Diksha Omer digitally signed the disclosure documents on April 02, 2026, ensuring proper documentation and regulatory compliance for all announced changes.